- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03250234
Carbohydrate Availability and microRNA Expression
Influence of Carbohydrate Availability on Skeletal Muscle and Circulating microRNA Expression
This investigation will examine the impact of skeletal muscle glycogen stores on skeletal muscle and circulating microRNA expression and exogenous carbohydrate oxidation.
Primary Objective Determine the influence of carbohydrate availability (e.g., glycogen depletion and repletion) on skeletal muscle microRNA expression, and if changes in circulating microRNA are reflective of changes in skeletal muscle microRNA.
Secondary Objective Determine how initiation of exercise with adequate or low glycogen stores effects exogenous carbohydrate efficiency.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Twelve, normal weight, healthy, physically active men and women will complete a glycogen depletion protocol, cycling at various intensities until failure. Participants will then consume a carbohydrate (CHO: 1 g/kg/hr) or an energy free control (CON) beverage matched for taste and color during the first 3-hr post glycogen depletion. For the remainder of the day participants will consume a diet designed to adequately (6.0 g CHO/kg/d) or inadequately (1.2 g CHO/kg/d) replenish glycogen stores. The following day participants will to complete 80-min of steady-state (~60% VO2peak) cycle ergometry consuming carbohydrate at a rate of 1.8 g/min enriched with a stable isotope of carbon to determine exogenous carbohydrate efficiency when glycogen stores are low or adequate at the onset of exercise.
Following a minimum 7-d washout period volunteers will return to the laboratory to complete the second arm of the investigation. To ensure glycogen stores are similar between volunteers on testing day, 48-hrs prior to testing all volunteers will complete a glycogen depletion protocol and then consume a diet providing 6.0 g/kg/d carbohydrate to replenish glycogen stores.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Natick, Massachusetts, United States, 01760
- USARIEM
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Men and women aged 18 - 39 years
- Weight stable (±5 lbs) for at least 2 months prior to the start of the study
- Body mass index (BMI) between 18.5-30 kg/m2
- Recreationally active based on assessment of physical activity history 2-4 days per week aerobic and/or resistance exercise
- Refrain from taking any NSAIDS (i.e., aspirin, Advil®, Aleve®, Naprosyn®, or any aspirin-containing product for 10 days before and at least 5 days AFTER each muscle biopsy. (*Tylenol® or acetaminophen is ok to use if needed for discomfort)
- Refrain from the use of alcohol and nicotine for the duration of the study
- Females must be on contraception (e.g., oral birth control, NuvaRing®, Depo Provera®, etc.)
- Supervisor approved leave status for federal civilian employees working within the US Army Natick Soldier Systems Center
Exclusion Criteria:
- Metabolic or cardiovascular abnormalities, gastrointestinal disorders (i.e., kidney disease, diabetes, cardiovascular disease, etc.)
- Disease or medication (i.e., diabetes medications, statins, corticosteroids, etc) that affects macronutrient utilization and/or the ability to participate in strenuous exercise
- Allergies or intolerance to foods (including but not limited to lactose intolerance/milk allergy), vegetarian practices, or medications (including, but not limited to, lidocaine or phenylalanine) to be utilized in the study
- Anemia (HCT < 38) and Sickle Cell Anemia/Trait
- Abnormal prothrombin time (PT)/ partial thromboplastin time (PTT) test or problems with blood clotting
- Present condition of alcoholism, use of nutritional/sports supplements, anabolic steroids, or other substance abuse issues
- Musculoskeletal injuries that compromise the ability to exercise
- Blood donation within 8 weeks of beginning the study
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
OTHER: Adequate Carbohydrate
Carbohydrate beverage (1 g/kg/hr) Adequate carbohydrate diet 6.0 g/kg/d
|
During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
|
|
OTHER: Low Carbohydrate
Non-nutritive control beverage.
Low carbohydrate diet 1.2 g/kg/d
|
During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage. For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fold Change in microRNA Expression From Baseline
Time Frame: 24 hours
|
Determine the influence of low or adequate glycogen on expression of skeletal muscle and circulating microRNA.
Expression of microRNA was determined using real time polymerase chain reaction analysis.
microRNA expressions were calculated as a fold change relative to baseline.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exogenous Carbohydrate Oxidation
Time Frame: 80 minutes
|
Determine how initiation of exercise with adequate or low glycogen stores effects exogenous carbohydrate efficiency.
Exogenous carbohydrate oxidation was measured using an oral 13C-glucose isotope that was consumed in the study carbohydrate drink during steady-state cycling.
Breath samples were collected during exercise and analyzed using isotope ratio mass spectrometry to calculate exogenous carbohydrate oxidation rates.
|
80 minutes
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 17-17H
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glycogen Depletion
-
Per Bendix JeppesenAarhus University Hospital; University of AarhusUnknown
-
Helga EllingsgaardCompletedGlycogen DepletionDenmark
-
Maastricht University Medical CenterUnilever R&DCompletedFasting | Fatty Liver, Nonalcoholic | Glycogen Depletion | Meal TimeNetherlands
-
University of CopenhagenCompletedInsulin Sensitivity | Glycogen DepletionDenmark
-
PepsiCo Global R&DCompletedMuscle Soreness | Muscle Recovery | Glycogen DepletionUnited States
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompleted
-
Columbia UniversityUniversitat Autonoma de Barcelona; Instituto de Salud Carlos III; University... and other collaboratorsActive, not recruitingThymidine Kinase 2 Deficiency | Mitochondrial DNA Depletion Syndrome 2 Myopathic TypeUnited States
-
Duke UniversityKriya TherapeuticsRecruitingGlycogen Storage Disease VI | GLYCOGEN STORAGE DISEASE IXa1 | GLYCOGEN STORAGE DISEASE IXa2 | Glycogen Storage Disease IXB | Glycogen Storage Disease IXC | GSD 9 (All Subtypes) | GSD 6United States
-
Connecticut Children's Medical CenterGlobal Center for Glycogen Storage Disease held at the Jewish Community FoundationRecruitingGlycogen Storage Disease Type I | Glycogen Storage Disease Type IA | Glycogen Storage Disease Type IB | Glycogen Storage Disease XiUnited States
Clinical Trials on Adequate Carbohydrate
-
Lance BollingerNational Aeronautics and Space Administration (NASA)CompletedMuscle Weakness | Sleep Disturbance | Quadriceps Muscle AtrophyUnited States
-
University of Alabama at BirminghamCompletedObesity, Childhood | Overweight, ChildhoodUnited States
-
University of TennesseeCompleted
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes Mellitus | Diabetes Complications | Sarcopenia | Sarcopenic ObesityItaly
-
Chinese PLA General HospitalLu jiang hospitalCompletedMyocardial Infarction | Contrast-induced NephropathyChina
-
NYU Langone HealthCompletedSleep | Metabolic SyndromeUnited States
-
Assistance Publique Hopitaux De MarseilleUnknown
-
University of Illinois at Urbana-ChampaignAbbott NutritionCompletedDietary Modification | Cognitive Ability, GeneralUnited States
-
Unilever R&DCompleted
-
Sunnybrook Health Sciences CentreCompletedSepsis | Mortality | Bacteremia | Critically Ill | Intensive Care | AntimicrobialNew Zealand, United States, Canada, Australia, Switzerland, Saudi Arabia, Israel